USA – Ordaōs, a New York-based biotechnology company designing mini-proteins to help drug hunters deliver life-saving treatments, raised $5M in Seed funding.
The round was led by Middleland Capital’s VTC Ventures with participation from Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, and Citta Capital. Led by CEO David Longo, Ordaōs is a human-enabled, machine-driven drug design company that leverages proprietary multitask meta-learning and reinforcement learning to create mini-proteins that enable targeted therapies to reduce patient suffering, improve health, and extend life.Ordaōs uses The Ordaōs Design Engine, to deliver true protein property design – leveraging continuous learning loops and proprietary data sets to translate human-targeted product criteria into machine-designed mini-proteins. Starting with amino acids, the Design Engine generates, appraises, and ranks billions of protein sequences and hundreds of thousands of protein structures and properties to create customized miniPRO™ proteins. These proteins are then rapidly evaluated in vitro to provide intelligent feedback on multiple design objectives including protein structure, binding specificity and affinity, solubility, stability, immunogenicity, and developability. This iterative process delivers optimized mini-proteins to meet the client’s specific molecular target product profile (mTPP). 26/08/2022
